Read by QxMD icon Read

Therapeutic Drug Monitoring

Laureen A Lammers, Roos Achterbergh, Marcel C M Pistorius, Yuma Bijleveld, Emmely M de Vries, Anita Boelen, Heinz-Josef Klümpen, Johannes A Romijn, RonA A Mathôt
BACKGROUND: The metabolic activity of P450 enzymes in vivo can be determined by using selective probe drugs. The simultaneous administration of multiple CYP-specific probe drugs is commonly referred to as the "cocktail approach." Disadvantages of a cocktail are large volumes of samples required for analysis and time-consuming analyses. The aim of this study was to develop and validate a simplified but sensitive method for the simultaneous quantification of five probe drugs (caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), omeprazole (CYP2C19), and S-warfarin (CYP2C9)) in a previously validated cocktail using an LC-MS/MS method...
October 19, 2016: Therapeutic Drug Monitoring
R Brent Dixon, Amitava Dasgupta
BACKGROUND: We evaluated the analytical performance of the DRI hydrocodone/hydromorphone assay by comparing semi-quantitative values obtained by this assay with values obtained by a liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) method. We also evaluated the possibility of lowering the cutoff of the DRI assay from 300 to 100 ng/mL. MATERIALS AND METHODS: We compared semi-quantitative values obtained by the DRI assay in 97 specimens with values obtained by using the LC-MS/MS method including 10 specimens containing hydrocodone and/ or hydromorphone concentrations between 105...
October 19, 2016: Therapeutic Drug Monitoring
Lawrence C Ku, Huali Wu, Rachel G Greenberg, Kevin D Hill, Daniel Gonzalez, Christoph P Hornik, Alysha Berezny, Jeffrey T Guptill, Wenlei Jiang, Nan Zheng, Michael Cohen-Wolkowiez, Chiara Melloni
BACKGROUND: Defining a drug's therapeutic index (TI) is important for patient safety and regulating the development of generic drugs. For many drugs, the TI is unknown. A systematic approach was developed to characterize the TI of a drug using therapeutic drug monitoring and electronic health record (EHR) data with pharmacokinetic (PK) modeling. This approach was first tested on phenytoin, which has a known TI, and then applied to lamotrigine, which lacks a defined TI. METHODS: Retrospective EHR data from patients in a tertiary hospital were used to develop phenytoin and lamotrigine population PK models and to identify adverse events (anemia, thrombocytopenia, and leukopenia) and efficacy outcomes (seizure-free)...
October 19, 2016: Therapeutic Drug Monitoring
Masahiro Ohgami, Masato Homma, Yoshiharu Suzuki, Kanako Naito, Motoko Yamada, Shoichi Mitsuhashi, Fumie Fujisawa, Hiroshi Kojima, Takayuki Kaburagi, Keiko Uchiumi, Yutaka Yamada, Hiroko Bando, Hisato Hara, Keiji Takei
BACKGROUND: Lapatinib and erlotinib are used for cancer treatment, showing large interindividual variability. Therapeutic drug monitoring may be useful for assessing the clinical outcomes and adverse events. A simple high-performance liquid chromatography ultraviolet method was developed for the determination of lapatinib and erlotinib in human plasma. METHODS: An aliquot of plasma sample spiked with IS was treated with acetonitrile to precipitate the proteins. Lapatinib and erlotinib were separated on an octadecylsilyl silica-gel column using a mobile phase consisting of acetonitrile, methanol, water, and trifluoroacetic acid (26:26:48:0...
October 17, 2016: Therapeutic Drug Monitoring
Valentina Franco, Roberto Marchiselli, Cinzia Fattore, Elena Tartara, Giovambattista De Sarro, Emilio Russo, Emilio Perucca
BACKGROUND: Perampanel, a new specific non-competitive AMPA receptor antagonist, has been recently approved in the United States and the European Union for the adjunctive treatment of focal seizures and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy. A positive relationship between plasma perampanel concentration and improvement in seizure control has been identified in regulatory trials, suggesting that therapeutic drug monitoring (TDM) could be useful in optimizing clinical response in patients with epilepsy treated with perampanel...
October 6, 2016: Therapeutic Drug Monitoring
M Herbrink, N de Vries, H Rosing, A D R Huitema, B Nuijen, J H M Schellens, J H Beijnen
BACKGROUND: A liquid chromatography/tandem mass spectrometry assay was developed to facilitate therapeutic drug monitoring (TDM) for 10 anticancer compounds (dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, sunitinib, and vemurafenib) and the active metabolite, N-desethyl-sunitinib. METHODS: The TDM assay is based on reversed-phase chromatography coupled with tandem mass spectrometry in the positive ion mode using multiple-reaction monitoring for analyte quantification...
October 5, 2016: Therapeutic Drug Monitoring
Kevin Bihan, Qin Lu, Manon Enjalbert, Maxime Apparuit, Olivier Langeron, Jean-Jacques Rouby, Christian Funck-Brentano, Noel Zahr
BACKGROUND: Colistin is a polypeptide antibiotic from the polymyxin E group used for the treatment of infections caused by multidrug resistant gram-negative bacteria. The main constituents, accounting for approximately 85% of this mixture, are colistinA (polymyxin E1) and colistin B (polymyxin E2). The aim of this study was to develop and validate new and fast methods of quantification of colistin A&B and its precursors (CMS A&B) by Liquid Chromatography-tandem Mass Spectrometry (UPLC-MS) in plasma and urine with short pre-treatment and run times...
September 27, 2016: Therapeutic Drug Monitoring
Keita Hirai, Hidetoshi Ishii, Takayuki Shimoshikiryo, Tatsuki Shimomura, Daiki Tsuji, Kazuyuki Inoue, Toshihiko Kadoiri, Kunihiko Itoh
BACKGROUND: Augmented renal clearance (ARC) has frequently been observed in critically ill patients. The risk factors for ARC in patients, including those in the general ward, and their influences on vancomycin (VCM) treatment remain unclear. The aims of this study were to investigate the risk factors for ARC and to evaluate the influence of ARC on the pharmacokinetic parameters of VCM. METHODS: This study included a total of 292 patients with VCM treatment who had normal serum creatinine concentrations...
September 23, 2016: Therapeutic Drug Monitoring
James Ermer, Mary Corcoran, Kenneth Lasseter, Patrick T Martin
BACKGROUND: This open-label, crossover study examined lisdexamfetamine dimesylate (LDX) and d-amphetamine pharmacokinetics in healthy adults after administration of an intact LDX capsule or after the capsule was emptied into orange juice or yogurt and the contents consumed. METHODS: Healthy adult volunteers (N = 30) were administered a 70-mg LDX capsule or the contents of a 70-mg capsule mixed with yogurt or orange juice using a three-way crossover design. Blood samples were collected serially for up to 96 h postdose...
September 20, 2016: Therapeutic Drug Monitoring
Atsuko Tanaka, Ikuko Yano, Keiko Shinsako, Eriko Sato, Masahide Fukudo, Satohiro Masuda, Toshinari Yamasaki, Tomomi Kamba, Osamu Ogawa, Kazuo Matsubara
BACKGROUND: Everolimus has been used for the treatment of unresectable or metastatic renal cell carcinoma (RCC). Here, we measured blood concentrations of everolimus to obtain the population pharmacokinetic parameters and to examine the relationship between blood concentration and clinical outcomes. METHODS: Twenty-two Japanese patients were enrolled. Blood samples were collected before and 2, 4, 8, and 24 h after drug administration on days 1 and 8 of everolimus therapy (5 or 10 mg) for inpatients; occasional samples were collected for outpatients...
September 19, 2016: Therapeutic Drug Monitoring
Sabina Bialkowski, Christine E Staatz, Julia Clark, Rachael Lawson, Stefanie Hennig
BACKGROUND: The pharmacokinetics of gentamicin in pediatric febrile neutropenia patients is described and the adequacy of initial dosing of once daily gentamicin assessed at Queensland's largest Children's Hospital. METHODS: Data were retrospectively collected from all pediatrics with febrile neutropenia admitted over a two-year period who had at least two gentamicin concentration-time measurements (a paired set within one dosing interval). Gentamicin clearance (CL), volume of distribution (Vd), area under the concentration-time curve from 0 to 24 hours post-dose (AUC0-24), and maximum concentration (Cmax) values were estimated using log-linear regression using each paired set...
September 16, 2016: Therapeutic Drug Monitoring
Emaad Abdel-Kahaar, Thomas Giese, Claudia Sommerer, Hannah Rieger, Maria Shipkova, Eberhard Wieland
BACKGROUND: Analysis of residual gene expression (RGE) of NFAT-regulated genes has been developed as a pharmacodynamic biomarker to monitor therapy with calcineurin inhibitors (CNI). The availability of commercial primer sets (Search-LC, Heidelberg) and the well-established assay protocol make this biomarker a promising candidate to be utilized clinically in different laboratories. However, implementation of the method in routine practice requires analytical robustness and comparable results across laboratories...
September 16, 2016: Therapeutic Drug Monitoring
Yasuyoshi Ishiwata, Masashi Nagata, Takafumi Arai, Misato Makiishi, Maho Yoshikawa, Hiromitsu Takahashi, Hitoshi Kohsaka, Masato Yasuhara
BACKGROUND: Although azole antifungal agents have been shown to affect the pharmacokinetics of calcineurin inhibitors such as tacrolimus and cyclosporine by inhibiting drug metabolism, there are few clinical reports on drug interactions between miconazole oral gel and calcineurin inhibitors. In the present study, the effects of miconazole oral gel on the blood concentrations of tacrolimus and cyclosporine were investigated. METHODS: In this retrospective study, 18 patients concomitantly administered miconazole oral gel and tacrolimus (9 for dermatomyositis, 3 for myasthenia gravis, 2 for systemic lupus erythematosus, 2 for rheumatoid arthritis, 1 for polymyositis, 1 for prevention of graft-versus-host disease post bone marrow transplantation), and 15 patients concomitantly administered miconazole oral gel and cyclosporine (11 for interstitial pneumonia, 2 for pemphigus, 1 for eosinophilic granulomatosis with polyangiitis, 1 for systemic lupus erythematosus) were evaluated...
August 23, 2016: Therapeutic Drug Monitoring
Véronique Loustaud-Ratti, Marianne Maynard, Sylvie Thevenon, Pierre Pradat, Annick Rousseau, Sophie Alain, Paul Deny, Marie-Claude Gagnieu, Albert Tran, Thông Dao, Christine Silvain, Françoise Lunel-Fabiani, Nicolas Picard, Irène Zublena, Pierre Marquet, Christian Trepo
BACKGROUND: ribavirin exposure after the first dose (D0AUC0-4h) > 1755μg.h/L is predictive of sustained virological response (SVR) in hepatitis C-infected patients treated with peginterferon and ribavirin. The aim of this study was to test the benefit of ribavirin early dose adjustment based on this target in naïve genotype 1-infected patients. METHODS: multicenter randomized controlled trial with two parallel groups; Fixed-dose (FD) group: standard of care in 2010-2011, i...
August 23, 2016: Therapeutic Drug Monitoring
Shohei Matsuda, Tomoko Imazu, Ryuji Kimura, Mamoru Nakamura, Atsushi Matsumoto, Teruo Murakami, Yorinobu Maeda
BACKGROUND: A recommendation for dosage adjustment of dabigatran etexilate, a prodrug of dabigatran, seems to be desirable based on creatinine clearance to avoid bleeding and stroke. METHODS: Outpatients and inpatients having a history of cardioembolic stroke or atrial fibrillation were included. After taking dabigatran etexilate orally (75 - 150 mg twice daily) for at least 1 week, plasma trough concentration (Ctrough, ng/ml) of dabigatran and creatinine clearance (CLcr, mL/min) of patients according to Cockcroft and Gault equation were determined...
August 23, 2016: Therapeutic Drug Monitoring
Patrick J Lindsay, Stuart E Bond, Dip Pharm Prac, Ross Norris, Deborah Je Marriott, Spiros Miyakis
BACKGROUND: Posaconazole therapeutic drug monitoring (TDM) is recommended to promote effective antifungal prophylaxis, but its utility has yet to be optimized. Breakthrough invasive fungal infections have been reported with serum concentrations <700 μg/L, but there is little evidence to determine the optimal serum concentration for efficacy or concentrations associated with toxicity. Challenges for effective monitoring are greater in settings without posaconazole TDM facilities due to the long turnaround time prior to receipt of results...
August 19, 2016: Therapeutic Drug Monitoring
Anne-Sophie Bargnoux, Thibault Sutra, Stéphanie Badiou, Nils Kuster, Anne Marie Dupuy, Georges Mourad, Georges-Philippe Pageaux, Moglie Le Quintrec, Jean-Paul Cristol
BACKGROUND: Many patients are maintained at the lower end of the tacrolimus (TAC) reference range (3-7 ng/mL), requiring the use of analytical methods displaying a very low limit of quantification for their follow-up. Therefore the new Dimension TAC, based on affinity chrome-mediated immunoassay (ACMIA) technology, was evaluated on the Dimension EXL Integrated Chemistry System (Siemens Healthcare Diagnostics Inc). The aims of this study were 1) to evaluate the analytical performances with special emphasis on sensibility at low levels of TAC, 2) to compare the results with an ultra-performance liquid chromatography tandem mass spectrometry (UPLC/MS/MS) method...
August 4, 2016: Therapeutic Drug Monitoring
P K C Janssen, N A Foudraine, D M T Burgers, C Neef, J L M L le Noble
INTRODUCTION: Cefuroxime is frequently prescribed as an antimicrobial therapy in critically ill patients. The aim of this study was to develop a new intravenous dosing strategy for cefuroxime in critically ill patients undergoing continuous venovenous hemofiltration with regional citrate anticoagulation (RCA-CVVH) by analyzing its extracorporeal removal and pharmacokinetic (PK) parameters. METHODS: Nine critically ill patients treated with intravenous cefuroxime and RCA-CVVH and a phosphate-containing replacement fluid were investigated...
August 4, 2016: Therapeutic Drug Monitoring
Linda Aurpibul, Sirinya Teerananchai, Wasana Prasitsuebsai, Tavitiya Sudjaritruk, Pope Kosalaraksa, Nia Kurniati, Khanh Huu Truong, Viet Chau Do, Lam Van Nguyen, Kulkanya Chokephaibulkit, Thida Singtoroj, Stephen J Kerr
BACKGROUND: Failure rates of second-line boosted protease inhibitor antiretroviral therapy regimens in children rise over time. Therapeutic drug monitoring (TDM) can contribute to assessments of adherence. The authors assessed the performance characteristics of the US DHHS-recommended lopinavir (LPV) concentration of 1.0 mg/L for predicting virologic failure (VF) and intermediate-to-high level LPV resistance in Asian children. MATERIALS AND METHODS: LPV concentration, HIV RNA level, and adherence data from study participants in Indonesia, Thailand, and Vietnam receiving second-line LPV-based ART and followed for ≥24 weeks were analyzed...
August 1, 2016: Therapeutic Drug Monitoring
Janet Lock, Raj K Patel, Carl Brookes, Jignesh P Patel
No abstract text is available yet for this article.
July 29, 2016: Therapeutic Drug Monitoring
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"